An ambitious pharmaceutical chapter in TTIP that aligns regulatory regimes and reduces duplicative costs will increase EU export of pharmaceuticals by €9 billion. Furthermore, it will provide 19,000 highly productive and qualified jobs in the EU pharmaceutical industry and 60,000 additional jobs in related industries in the EU.
Such an agreement will also benefit EU patients who get increased choice and improved access to new pharmaceutical products.
Today, Martin Thelle presents the results to members of the European Parliament